Clareo Health | Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
Participant has provided signed informed consent before any study-specific screening procedures
Participant has histopathologically confirmed primary colorectal, gastric or ovarian cancer or PDAC
Participant has known or suspected PC from the tumor of origin. Suspicion may be based on imaging or clinical findings.
Participant is scheduled for peritoneal surgery with curative intent, surgical exploration, or laparoscopy, with either: a. No neoadjuvant treatment received, treatment-naïve (i.e., undergoing upfront surgery or laparoscopy) b. Completed systemic treatment (which may include neoadjuvant chemotherapy) before GEH300079 ( 68Ga) PET/CT Imaging Visit
Participant has Eastern Cooperative Oncology Group (ECOG) performance status ≤2
Participant is able and willing to comply with all study procedures as described in the protocol
You may not be if
Participant is pregnant or breast-feeding, or sexually active and not using or not willing to use an acceptable form of birth control from screening up to 30 days after receiving the investigational medicinal product (IMP)
Participant has a known disorder that, in the opinion of the investigator, will impact the study procedures
Participant needs any intervention that would delay study participation
Participant has non-resectable extra-abdominal metastasis and/or \>3 hepatic metastases on standard work up
Participant will not be able to complete the study, based on their anticipated life expectancy
Participant has active bacterial, viral, or fungal infection requiring systemic antibacterial, anti-viral or antifungal therapy (topical medications are permitted)
Participant has renal function impairment as defined by:
1. For Phase 2: estimated glomerular filtration rate less than 60 mL/min
2. For Phase 3: estimated glomerular filtration rate less than 30 mL/min
Participant has severe hepatic function impairment as defined by:
1. Aspartate aminotransferase (serum glutamic-oxaloacetic transaminase) and alanine aminotransferase (serum glutamic-pyruvic transaminase): ≤2.5 × upper limit of normal (ULN; ≤5 × ULN for participants with liver metastases)
2. Bilirubin: ≤1.5 × ULN or direct bilirubin ≤ULN for participants with total bilirubin levels \>1.5 × ULN
Participant has autoimmune disease that required systemic treatment in the past 2 years. Replacement therapy (e.g., thyroxine, insulin, or physiologic corticosteroid) is allowed
Participant has serious co-morbidities or serious non-malignant disease that in the opinion of the investigator, could compromise participant safety and/or protocol objectives
Participant either received or is planning to receive any other investigational agent within the 28 days prior to the first imaging visit or during study participation (with the exception of the 3-month follow-up period)
Participant has known or suspected hypersensitivity to any excipients used in GEH300079 (68Ga)
Participant has severe claustrophobia, is unable to lie flat or fit into the scanner, or is unable to tolerate the PET/CT scan for any reason
(Phase 3 only) Participant was previously included in Phase 2 of this study
